Novartis to Acquire Myricx Bio to Expand Next-Generation ADC Portfolio
Novartis has signed an agreement to acquire Myricx Bio, a privately owned biotechnology company based in the UK that is developing a novel class of antibody-drug conjugates (ADCs) featuring N-myristoyltransferase inhibitor (NMTi) payloads.
The acquisition is expected to enhance Novartis' oncology pipeline by adding next-generation targeted conjugates with an innovative payload mechanism. Myricx's technology is designed to selectively deliver an NMTi payload to cancer cells, offering a differentiated approach that could overcome some of the challenges associated with widely used ADC payloads, ...
